TerminatedPhase 2NCT00557830
Randomized Study of Sorafenib Dose Escalation in Patients With Previously Untreated Metastatic Renal Cell Carcinoma
Studying Acquired cystic disease-associated renal cell carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Accelerated Community Oncology Research Network
- Principal Investigator
- Vasily Assikis, MDAcorn Cardiovascular, Inc.
- Intervention
- Sorafenib Escalated Dose(drug)
- Enrollment
- 12 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2008 – 2011
Study locations (13)
- Clopton Clinic, Jonesboro, Arkansas, United States
- Wilshire Oncology Medical Group, Inc., La Verne, California, United States
- Advanced Medical Specialties, Miami, Florida, United States
- Northeast Georgia Cancer Care, Athens, Georgia, United States
- Peachtree Hematology Oncology Consultants, Atlanta, Georgia, United States
- Central Georgia Cancer Care, Macon, Georgia, United States
- Northwest Georgia Oncology Centers, Marietta, Georgia, United States
- Mid-Illinois Hematology and Oncology Associates, Ltd., Normal, Illinois, United States
- Hematology Oncology Centers of the Northern Rockies, Billings, Montana, United States
- Gaston Hematology and Oncology, Gastonia, North Carolina, United States
- Pacific Oncology, PC, Beaverton, Oregon, United States
- The Lancaster Cancer Center, Ltd, Lancaster, Pennsylvania, United States
- The West Clinic, Memphis, Tennessee, United States
Collaborators
Bayer
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00557830 on ClinicalTrials.govOther trials for Acquired cystic disease-associated renal cell carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06882486Post-immunotherapy Nephrectomy for Metastatic Kidney Cancer After Complete or Major Response to Systemic TherapyInstitut Paoli-Calmettes
- RECRUITINGPHASE1NCT07517198Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid TumorsExscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
- RECRUITINGNANCT06907095Cohort Evaluation of Body Fluids Early Detection of Cancer in High-risk IndividualsGustave Roussy, Cancer Campus, Grand Paris
- RECRUITINGNANCT07461090Laparoscopic Versus Open Nephrectomy : Clinical Effectivness and Cost AnalysisMenoufia University
- RECRUITINGNANCT07402109CBCT Guided Markerless SBRT for Renal Cell CancerErasmus Medical Center
- RECRUITINGPHASE1NCT07195682A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)Bristol-Myers Squibb
- RECRUITINGPHASE1NCT07006688A Study of an IDH1m Inhibitor in Participants With IDH1-Mutated Malignancies and Hepatic or Renal ImpairmentServier Bio-Innovation LLC
- RECRUITINGPHASE1, PHASE2NCT07219576Retifanlimab and Ruxolitinib In Solid MalignanciesUniversity of California, San Diego
See all trials for Acquired cystic disease-associated renal cell carcinoma →